Global Alpha Mannosidosis Market Report 2021 - Opportunities And Strategies, Market Forecast And Trends

1 Jun, 2021

The alpha mannosidosis market consists of sales of therapies for alpha mannosidosis (organizations, sole traders and partnerships) that provides treatment for alpha mannosidosis, which is a lysosomal storage disorder. Lysosomes are particles bound in membranes within cells that function as the primary digestive units. Alpha-mannosidosis is a rare genetic inherited condition that affects the organs and tissues of the person suffering from the disease. The treatment therapy focuses on detecting and preventing polysaccharide accumulations within mutant cells, which can cause harm to tissue, organs, and eventually death. Polysaccharides are defined as larger molecules composed of several linked sugar molecules.

Global Alpha Mannosidosis Market Size And Drivers:

The global alpha mannosidosis market is expected to grow from $7.50 million in 2020 to $8.89 million in 2021 at a compound annual growth rate (CAGR) of 18.6%. The growth is mainly due to increasing prevalence of alpha mannosidosis, use of orphan drugs, fee reductions and tax credits, increasing investment in the rare disease treatment and advancements in treatment drugs. The alpha mannosidosis market is expected to reach $17.91 million in 2025 at a CAGR of 19.1%. The increasing investments on research are expected to contribute to the growth of the alpha mannosidosis market in the forecast period.

Request For A Sample For The Global Alpha Mannosidosis Market Report:

Trends In The Global Alpha Mannosidosis Market

The advancements in treatment for alpha mannosidosis like pharmacological therapy are gaining traction in the alpha mannosidosis market. For instance, in 2018 – Chiesi Group, an international research-focused Healthcare company, announced that it has received a positive opinion recommending the marketing authorization of Velmanase Alfa, under the brand name Lamzede from the European Medicines Agency Committee for Medicinal Products for Human Use. Lamzede is an enzyme replacement therapy intended to provide or supplement natural alpha-mannosidase, an enzyme that helps with the degradation of mannose–rich oligosaccharides and thus prevents their accumulation in various tissues in the body.

Global Alpha Mannosidosis Market Segments:
The global alpha mannosidosis market is further segmented based on type and geography.
By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy
By Indication: Type I, Type II, Type III
By End-User: Hospitals, Specialty Clinics
By Geography: The global alpha mannosidosis market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America is the largest region in the alpha mannosidosis market in 2020.

Read More On The Report For The Global Alpha Mannosidosis Market At:

Alpha Mannosidosis Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides alpha mannosidosis market overviews, analyzes and forecasts market size and growth for the global alpha mannosidosis market, alpha mannosidosis market share, alpha mannosidosis market players, alpha mannosidosis market segments and geographies, alpha mannosidosis market’s leading competitors’ revenues, profiles and market shares. The alpha mannosidosis market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.